ArriVent and Alphamab Partner in $615.5 million collaboration for Novel ADC Cancer Treatments – GeneOnline

GeneOnline shared a post on LinkedIn:

“ArriVent BioPharma and Alphamab Oncology announce a $615.5 million collaboration to develop and commercialize novel antibody-drug conjugates (ADCs) for cancer treatment. This partnership leverages cutting-edge ADC technology and global commercialization expertise.”